01/07/2026 Ostuka reported positive Phase 3 results for sibeprenlimab in IgAN Ostuka reported positive Phase 3 results for sibeprenlimab in IgAN (Ref) Otsuka Pharmaceutical announced positive topline full study results from the Phase 3, VISIONARY/ NCT05248646 trial for VOYXACT® (sibeprenlimab-szsi; Anti-APRIL) in adults with primary IgA nephropathy (IgAN) at risk of disease progression. Sibeprenlimab demonstrated statistically significant stabilization of eGFR with evidence